Categories
Change Password!
Reset Password!
In moderate-to-severe papulopustular rosacea, DFD-29 outperforms doxycycline in achieving clear or almost clear skin at week 16.
A new study led by Alhasan Altayf et al. reports that DFD-29, a novel extended-release minocycline 40 mg formulation, delivers higher treatment success rates than doxycycline 40 mg in moderate-to-severe papulopustular rosacea (PPR), without compromising safety.
PPR is a chronic inflammatory dermatologic ailment marked by persistent facial erythema, pustules, and papules. In this systematic review and meta-analysis, researchers explored PubMed, Cochrane Library, and ClinicalTrials.gov to identify randomized controlled trials (RCTs) directly comparing DFD-29 (40 mg) with doxycycline (40 mg) in PPR. Investigator’s Global Assessment (IGA) success at week 16, marked as a score of 0 (clear) or 1 (almost clear) with a minimum of two-grade betterment from the baseline was the key endpoint.
Serious adverse events (SAEs), treatment-emergent adverse events (TEAEs), and specific adverse events such as diarrhea, vertigo, and headache were the safety endpoints. Three head-to-head RCTs—MVOR-1, MVOR-2, and Tsianakas 2021—met the inclusion criteria, encompassing a total of 593 patients. The pooled analysis depicted that DFD-29 considerably improved IGA success rates compared with doxycycline. The odds ratio (OR) for achieving IGA success at week 16 was 2.86, indicating nearly a threefold higher likelihood of treatment success. Statistical heterogeneity was low, reinforcing the robustness of the efficacy findings.
In terms of safety and tolerability, no prominent inter-group differences were observed. The odds ratio for TEAEs was 1.28, while SAEs showed an OR of 1.06. Rates of specific adverse events were also comparable: diarrhea (OR 1.28), vertigo (OR 1.00), and headache (OR 0.83). Heterogeneity across safety outcomes was negligible. Overall, the findings suggest that low-dose minocycline (40 mg) offers superior efficacy over doxycycline (40 mg) for moderate-to-severe PPR, while maintaining a similar safety profile.
Archives of Dermatological Research
Efficacy and safety of low-dose minocycline (DFD-29) versus doxycycline in papulopustular rosacea: a systematic review and meta-analysis
Alhasan Altayf et al.
Comments (0)